These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35524036)

  • 21. In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
    Med Lett Drugs Ther; 2022 May; 64(1650):79. PubMed ID: 35536124
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.
    Singh AK; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102436. PubMed ID: 35245858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
    Phizackerley D
    BMJ; 2024 Jan; 384():q53. PubMed ID: 38224977
    [No Abstract]   [Full Text] [Related]  

  • 25. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
    Crabtree TSJ; Adamson K; Reid H; Barnes D; Sivappriyan S; Bickerton A; Gallen IW; Field BCT; Idris I; Ryder REJ;
    Diabetes Obes Metab; 2022 Jul; 24(7):1398-1401. PubMed ID: 35322528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
    Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
    J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
    Zaheer H; Hammad Zaheer M
    Diabetes Res Clin Pract; 2024 Jul; 213():111759. PubMed ID: 38925293
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
    Villela R; Correa R
    J Investig Med; 2022 Jan; 70(1):3-4. PubMed ID: 34949728
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
    Powell J; Piszczatoski C; Taylor JR
    Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
    Herrington WG; Haynes R
    N Engl J Med; 2024 Jul; 391(2):178-179. PubMed ID: 38986062
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
    Overgaard RV; Lindberg SØ; Thielke D
    Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
    Aroda VR; Blonde L; Pratley RE
    Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.